全文获取类型
收费全文 | 1266469篇 |
免费 | 97170篇 |
国内免费 | 1588篇 |
专业分类
耳鼻咽喉 | 16589篇 |
儿科学 | 41211篇 |
妇产科学 | 35118篇 |
基础医学 | 189419篇 |
口腔科学 | 35046篇 |
临床医学 | 118091篇 |
内科学 | 247751篇 |
皮肤病学 | 27564篇 |
神经病学 | 102073篇 |
特种医学 | 47553篇 |
外国民族医学 | 272篇 |
外科学 | 179995篇 |
综合类 | 25788篇 |
现状与发展 | 3篇 |
一般理论 | 570篇 |
预防医学 | 104672篇 |
眼科学 | 28219篇 |
药学 | 93046篇 |
6篇 | |
中国医学 | 1971篇 |
肿瘤学 | 70270篇 |
出版年
2018年 | 13739篇 |
2017年 | 10564篇 |
2016年 | 11570篇 |
2015年 | 13321篇 |
2014年 | 18296篇 |
2013年 | 27835篇 |
2012年 | 38155篇 |
2011年 | 40588篇 |
2010年 | 23396篇 |
2009年 | 22601篇 |
2008年 | 38339篇 |
2007年 | 40965篇 |
2006年 | 40557篇 |
2005年 | 39703篇 |
2004年 | 38118篇 |
2003年 | 36470篇 |
2002年 | 35308篇 |
2001年 | 56373篇 |
2000年 | 57329篇 |
1999年 | 48110篇 |
1998年 | 12603篇 |
1997年 | 11438篇 |
1996年 | 11822篇 |
1995年 | 11923篇 |
1994年 | 11131篇 |
1993年 | 10411篇 |
1992年 | 38384篇 |
1991年 | 37892篇 |
1990年 | 36676篇 |
1989年 | 35469篇 |
1988年 | 32854篇 |
1987年 | 32194篇 |
1986年 | 30682篇 |
1985年 | 28941篇 |
1984年 | 22063篇 |
1983年 | 19248篇 |
1982年 | 11390篇 |
1981年 | 10336篇 |
1979年 | 20996篇 |
1978年 | 15436篇 |
1977年 | 12790篇 |
1976年 | 11847篇 |
1975年 | 12855篇 |
1974年 | 15645篇 |
1973年 | 15404篇 |
1972年 | 14569篇 |
1971年 | 13615篇 |
1970年 | 12832篇 |
1969年 | 12128篇 |
1968年 | 11257篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
71.
72.
Schaefer Jordan K. Barnes Geoffrey D. Sussman Jeremy B. Saini Sameer D. Caverly Tanner J. Read Susan Zikmund-Fisher Brian J. Kurlander Jacob E. 《Journal of thrombosis and thrombolysis》2022,54(4):639-646
Journal of Thrombosis and Thrombolysis - Recent trials suggest that aspirin for primary prevention may do more harm than good for some, including adults over 70 years of age. We sought to... 相似文献
73.
Lillyblad Matthew P. Qadri Ghaziuddin A. Weise Brynn E. Smith Claire S. St. Hill Catherine Tierney David M. Melamed Roman R. 《Journal of thrombosis and thrombolysis》2022,54(4):605-615
Journal of Thrombosis and Thrombolysis - Alteplase treatment can cause a systemic coagulopathy although the incidence and contributory factors are unknown in pulmonary embolism (PE). Fixed-dosing... 相似文献
74.
Adam J. Rosenberg Yiu-Yin Cheung Fei Liu Todd E. Peterson James Silverman Ciaran M. Considine Daniel O. Claassen 《Journal of labelled compounds & radiopharmaceuticals》2022,65(8):223-229
(R)-[18F]MH.MZ ([18F]MH.MZ) is a promising positron emission tomography (PET) radiotracer for in vivo study of the 5-HT2A receptor. To facilitate clinical trials, a fully automated radiosynthesis procedure for [18F]MH.MZ was developed using commercially available materials on the iPhase Flexlab module. The overall synthesis time was 100 min with a radiochemical yield of 7 ± 0.9% (n = 3). The radiochemical purity was greater than 99% for [18F]MH.MZ with a molar activity of 361 ± 57 GBq/μmol (n = 3). The protocol described herein reliably provides [18F]MH.MZ that meets all relevant release criteria for a GMP radiopharmaceutical. 相似文献
75.
76.
The Patient - Patient-Centered Outcomes Research - 相似文献
77.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
78.
Dave E. W. van der Kruijssen Auke J. S. van der Kuil Geraldine R. Vink Cornelis J. A. Punt Johannes H. W. de Wilt Sjoerd G. Elias Miriam Koopman 《International journal of cancer. Journal international du cancer》2023,152(7):1360-1369
We studied the prognostic value of primary tumor sidedness in metastatic colorectal cancer over time and across treatment lines. Population data on synchronous metastatic colorectal cancer patients were extracted from the Netherlands Cancer Registry and SEER database. Pubmed, EMBASE and Cochrane library were searched for prospective studies on metastatic colorectal cancer to conduct a meta-analysis. Inclusion criteria consisted of metastatic disease, systemic treatment with palliative intent and specification of primary tumor location. Data were pooled using a random-effects model. For the population-based data, multivariable Cox models were constructed. The Grambsch-Therneau test was conducted to evaluate the potential time-varying nature of sidedness. Meta-regression incorporating treatment-line as variable was conducted to test the pre-specified hypothesis that the prognostic value of sidedness varies over time. Analysis of 12 885 and 16 160 synchronous metastatic colorectal cancer patients registered in the Netherlands Cancer Registry and SEER database, respectively, indicated a time-varying prognostic value of sidedness (P < .01). Thirty-one studies were selected for the meta-analysis (9558 patients for overall survival analysis). Pooled univariable hazard ratioleft-sided/right-sided for overall survival was 0.71 (95% CI: 0.65-0.76) in 1st-line, 0.76 (0.54-1.06) in 2nd-line and 1.01 (0.86-1.19) in 3rd-line studies. Hazard ratios were significantly influenced by treatment line (P = .035). The prognostic value of sidedness of the primary tumor in metastatic colorectal cancer patients treated with palliative systemic therapy decreases over time since diagnosis, suggesting that sidedness may not be a useful stratification factor in late-line trials. This decrease in prognostic value should be taken into account when providing prognostic information to patients. 相似文献
79.
80.
Mariano E. Menendez Suleiman Y. Sudah Patrick J. Denard 《Seminars in Arthroplasty》2022,32(3):644-649
BackgroundThe growing enthusiasm for the use of reverse shoulder arthroplasty (RSA) in the treatment of primary glenohumeral osteoarthritis (GHOA) with an intact rotator cuff is based on data derived from single-center studies with limited generalizability and follow-up. This study compared patient-reported outcomes (PROs) between RSA and total shoulder arthroplasty (TSA) for the treatment of primary GHOA with up to 5-year follow-up and examined temporal trends in the treatment of GHOA between 2012 and 2021.MethodsA retrospective review was performed on patients with primary GHOA undergoing primary arthroplasty surgery from the Surgical Outcomes System global registry between 2012 and 2021. PROs including the American Shoulder and Elbow Surgeons (ASES) score, Single Assessment Numeric Evaluation (SANE) score, and visual analog scale (VAS) for pain were compared between RSA and TSA at 1, 2, and 5 years postoperatively.ResultsA total of 4451 patients were included, with 2693 (60.5%) undergoing TSA and 1758 (39.5%) undergoing RSA. Both RSA and TSA provided clinically excellent outcomes at 1 year postoperatively (ASES: 80.8 ± 17.9 vs. 85.9 ± 15.2, respectively; SANE: 74.8 ± 24.7 vs. 79.5 ± 22.9; VAS pain: 1.3 ± 2.0 vs. 1.1 ± 1.7; all P < .05) that were maintained at 2 years (ASES: 81.3 ± 19.3 vs. 87.3 ± 14.9; SANE: 74.8 ± 26.2 vs. 79.7 ± 24.7; VAS pain: 1.3 ± 2.1 vs. 1.0 ± 1.6; all P < .05) and 5 years (ASES: 81.7 ± 16.5 vs. 86.9 ± 15.3; SANE: 71.6 ± 28.5 vs. 78.2 ± 25.9; VAS pain: 1.0 ± 1.7 vs. 1.0 ± 1.7; all P < .05), with statistical significance favoring TSA. After controlling for age and sex, there was an adjusted difference of 4.5 units in the ASES score favoring TSA (P = .005) at 5 years postoperatively but no differences in adjusted SANE (P = .745) and VAS pain (P = .332) scores. The use of RSA for GHOA grew considerably over time, from representing only 17% of all replacements performed for GHOA in 2012 to nearly half (47%) in 2021 (P < .001).ConclusionRSA as a treatment for GHOA with an intact rotator cuff seems to yield PROs that are largely clinically equivalent to TSA extending to 5 years postoperatively. The observed statistical significance favoring TSA appears to be of marginal clinical benefit based on established minimal clinically important differences and may be a result of the large sample size. Further research using more granular clinical data and examining differences in range of motion and complications is warranted as it may change the value analysis. 相似文献